Skip to main content
SpringerLink
Log in

Carbamazepine

  • Chapter
  • First Online:
Antiepileptic Drug Interactions

Abstract

Carbamazepine (Fig. 1) corresponds chemically to 5H-dibenz[b,f]azepine-5-carboxamide with an empirical formula of C15H12N2O and a molecular weight of 236.27.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Forsythe WI, Owens JR, Toothill C. Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. Dev Med Child Neurol. 1981;23:761–9.

    Article  PubMed  CAS  Google Scholar 

  2. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication and negative myoclonus after the addition of clobazam. Epilepsia. 1998;39:1115–8.

    Article  PubMed  CAS  Google Scholar 

  3. Johannessen SI, Strandjord RE, Munthe-Kaas AW. Lack of effect o clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine. Acta Neurol Scand. 1977;55:506–12.

    Article  PubMed  CAS  Google Scholar 

  4. Elger C, Halasz P, Maia J, Almeidas L, Soares-da-Silva P, on behalf of the BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454–63.

    Article  PubMed  CAS  Google Scholar 

  5. Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon SD, Perucca E, Engel J, editors. The treatment of epilepsy. 3rd ed. Oxford: Blackwell Publishing; 2009. p. 485–98.

    Chapter  Google Scholar 

  6. Altafullah I, Talwar D, Loewenson R, Olson K, Lockman LA. Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children. Epilepsy Res. 1989;4:72–80.

    Article  PubMed  CAS  Google Scholar 

  7. Wagner ML, Remmel RP, Graves NM, Leppik IE. Effect of felbamate on carbamazepine and its metabolites. Clin Pharmacol Ther. 1993;53:536–43.

    Article  PubMed  CAS  Google Scholar 

  8. Radulovic LL, Wilder BJ, Leppik IE, Bockbrader HN, Chang T, Posvar EL, Sedman AJ, Uthman BM, Erdman GR. Lack of interaction of gabapentin with carbamazepine and valproate. Epilepsia. 1994;35:155–61.

    Article  PubMed  CAS  Google Scholar 

  9. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50:459–71.

    Article  PubMed  CAS  Google Scholar 

  10. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20:20–3.

    Article  PubMed  Google Scholar 

  11. Malminiemi K, Keranen T, Kerttula T, Moilanen E, Ylitalo P. Effects of short-term lamotrigine on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther. 2000;38:540–5.

    PubMed  CAS  Google Scholar 

  12. Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 1998;39:183–7.

    Article  PubMed  CAS  Google Scholar 

  13. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from the randomized clinical trials. Epilepsy Res. 2005;64:1–11.

    Article  PubMed  CAS  Google Scholar 

  14. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217–9.

    Article  PubMed  CAS  Google Scholar 

  15. Browne TR, Feldman RG, Buchanan RA, Allen CA, Fawcett-Vickers L, Szabo GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983;33:414–8.

    Article  PubMed  CAS  Google Scholar 

  16. McKee PJW, Blacklaw J, Forrest G, Gillham RA, Walker SM, Connelly D, Brodie MJ. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994;37:27–32.

    Article  PubMed  Google Scholar 

  17. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1987;9:298–303.

    Article  PubMed  CAS  Google Scholar 

  18. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407–13.

    Article  PubMed  CAS  Google Scholar 

  19. Ferron GM, Sachdeo R, Partiot A, Fritz T, Althouse S, Troy SM. Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharmacol Ther. 2001;63(Suppl 2):18.

    Google Scholar 

  20. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–41.

    Article  PubMed  CAS  Google Scholar 

  21. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56:526–36.

    Article  PubMed  CAS  Google Scholar 

  22. Gustavson LE, Cato A, Boellner SW, Cao GX, Quian JX, Guenther HJ, Sommerville KW. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Am J Ther. 1998;5:9–16.

    Article  PubMed  CAS  Google Scholar 

  23. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996;37:774–80.

    Article  PubMed  CAS  Google Scholar 

  24. Mack CJ, Kuc S, Mulcrone SA, Pilley A, Grunewald RA. Interaction between topiramate and carbamazepine: two case reports and a review of clinical experience. Seizure. 2002;11:464–7.

    Article  PubMed  CAS  Google Scholar 

  25. Pisani F, Caputo M, Fazio A, Oteri G, Russo M, Spina E, Perucca E, Bertilsson L. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic interaction. Epilepsia. 1990;31:339–42.

    Article  PubMed  CAS  Google Scholar 

  26. McKee PJW, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res. 1992;11:193–8.

    Article  PubMed  CAS  Google Scholar 

  27. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res. 1999;34:199–205.

    Article  PubMed  CAS  Google Scholar 

  28. Sanchez-Alcaraz A, Quintana MB, Lopez E, Rodriguez I, Llopis P. Effect of vigabatrin on the pharmacokinetics of carbamazepine. J Clin Pharm Ther. 2002;27:427–30.

    Article  PubMed  CAS  Google Scholar 

  29. Jedrzejczak J, Dlawichowska E, Owczarek K, Majkowski J. Effect of vigabatrin addition on carbamazepine serum levels in patients with epilepsy. Epilepsy Res. 2000;39:115–20.

    Article  PubMed  CAS  Google Scholar 

  30. Ragueneau-Majlessi I, Levy RH, Bergen D, Garnet W, Rosenfeld W, Mather G, Shah J, Grundy JS. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004;62:1–11.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCL-Institute of Neurology Department of Clinical and Experimental Epilepsy, Queen Square, London, London

    P. N. Patsalos

  2. Epilepsy Society Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire, UK

    P. N. Patsalos

Authors
  1. P. N. Patsalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Patsalos, P.N. (2013). Carbamazepine. In: Antiepileptic Drug Interactions. Springer, London. https://doi.org/10.1007/978-1-4471-2434-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2434-4_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2433-7

  • Online ISBN: 978-1-4471-2434-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation